Maxime Cordonnier
Director of Finance/CFO bei AFYREN
Profil
Maxime Cordonnier is currently the Chief Financial Officer at Afyren SAS since 2019.
Prior to this, he held Director positions at Carbiolice SAS, Evertree SAS, and Yposkesi from 2016 to 2018.
He was also a Manager-Business Research at Lundbeck SAS from 2009 to 2010.
Mr. Cordonnier received his graduate degree from Imperial College London in 2005 and his undergraduate degree from École Centrale Paris in the same year.
Aktive Positionen von Maxime Cordonnier
Unternehmen | Position | Beginn |
---|---|---|
AFYREN | Director of Finance/CFO | 01.01.2019 |
Ehemalige bekannte Positionen von Maxime Cordonnier
Unternehmen | Position | Ende |
---|---|---|
Evertree SAS
Evertree SAS Chemicals: SpecialtyProcess Industries Evertree SAS produces plant-based chemicals. Its product SynerXiD is a family of proprietary, dry powder chemicals for industrial manufacturing. The company was founded by Anthony Parker and Joe Marcinko on February 16, 2016 and is headquartered in Compiegne, France. | Director/Board Member | 01.12.2018 |
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The private company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Director/Board Member | 01.06.2018 |
Carbiolice SAS
Carbiolice SAS Miscellaneous ManufacturingProducer Manufacturing Carbiolice SAS engages in the provision of biological technologies for plastics and synthetic fibers. The company was founded on June 14, 2016 and is headquartered in Riom, France. | Director/Board Member | 01.06.2018 |
Lundbeck SAS
Lundbeck SAS Pharmaceuticals: MajorHealth Technology Lundbeck SAS is a pharmaceutical laboratory, which focuses on neurology and psychiatry. The company was founded in 1992 and is headquartered in Paris La Defense, France. | Corporate Officer/Principal | 01.12.2010 |
Ausbildung von Maxime Cordonnier
Imperial College London | Graduate Degree |
École Centrale Paris | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AFYREN | Health Technology |
Private Unternehmen | 4 |
---|---|
Lundbeck SAS
Lundbeck SAS Pharmaceuticals: MajorHealth Technology Lundbeck SAS is a pharmaceutical laboratory, which focuses on neurology and psychiatry. The company was founded in 1992 and is headquartered in Paris La Defense, France. | Health Technology |
Carbiolice SAS
Carbiolice SAS Miscellaneous ManufacturingProducer Manufacturing Carbiolice SAS engages in the provision of biological technologies for plastics and synthetic fibers. The company was founded on June 14, 2016 and is headquartered in Riom, France. | Producer Manufacturing |
Evertree SAS
Evertree SAS Chemicals: SpecialtyProcess Industries Evertree SAS produces plant-based chemicals. Its product SynerXiD is a family of proprietary, dry powder chemicals for industrial manufacturing. The company was founded by Anthony Parker and Joe Marcinko on February 16, 2016 and is headquartered in Compiegne, France. | Process Industries |
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The private company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Health Technology |